Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Advanced Cancer 2 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Non-Muscle Invasive Bladder Neoplasms 1 Melanoma 1 Lymphoid Interstitial Pneumonia 1 Laryngeal Diseases 1 Endometrial Adenocarcinoma 1 Carcinoma, Squamous Cell 1 Advanced Gastric Cancer 1

Interventions

Oxaliplatin 5 Capecitabine 5 Paclitaxel 4 apatinib 3 Fluorouracil 3 Docetaxel 3 Cisplatin 3 S 1 (combination) 2 Leucovorin 2 titanium silicide 1 rucaparib 1 relatlimab 1 raltitrexed 1 pazopanib 1 olaparib 1 linrodostat 1 endostar protein 1 durvalumab 1 dacomitinib 1 capivasertib 1 camrelizumab 1 Sunitinib 1 SHR-1701 1 Nivolumab 1 Ipilimumab 1 HMPL-013 1 Epirubicin 1 Doxorubicin 1 CF regimen 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Gastric Cancer × linrodostat × Clear all

NCT02935634 2023-06-09

FRACTION-GC

Bristol-Myers Squibb

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡